NEW YORK — According to published reports, the U.S. could authorize emergency use of Moderna’s experimental COVID-19 vaccine in December with FDA approval. The company’s CEO Stéphane Bancel said if the company gets positive interim results in November from a large clinical trial. Bancel’s comments suggest Moderna’s timetable isn’t that far off from Pfizer’s, which
NEW YORK — Pfizer and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S.
NEW YORK — Pfizer and BioNTech SE announced Tuesday that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
WARREN, N.J. — GlaxoSmithKline said Thursday that it has closed a previously announced joint venture deal with Pfizer Inc. that will combine their respective consumer healthcare businesses. The move will create the world’s largest supplier of over-the-counter medications. The joint venture company will operate as GSK Consumer Healthcare. Pfizer owns a 32% equity stake in
NEW YORK— Pfizer and Mylan announced Monday a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of
NEW YORK — Pfizer announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46.
NEW YORK — GlaxoSmithKline Plc and Pfizer Inc. have struck a deal that will create the largest over-the-counter drug company in the world. GSK paved the way for a split into two companies, agreeing to create the consumer-health joint venture with Pfizer. GSK, according to the deal, with retain a 68% controlling stake in the new
ORLANDO, Fla. — Patients with certain rare, chronic and complex conditions can now obtain the medications that may improve or save their lives from AllianceRx Walgreens Prime, a leading central specialty and home delivery pharmacy. The hard-to-find drugs, called limited distribution drugs, treat such rare conditions as metastatic breast cancer, chronic liver disease, metastatic non-small cell
PARIS — A new report based on research by the Economist Intelligence Unit (EIU) and sponsored by Pfizer Vaccines assesses why, despite the evidence supporting the medical and cost-saving benefits of preventative health care measures, consumers regularly choose not to adopt them. Through interviews with leading international experts, the report reviews the psychological factors affecting consumer and
NEW YORK — Pfizer announced it will increase its commitment to U.S. manufacturing with a $465 million investment to build one of the most technically advanced sterile injectable pharmaceutical production facilities in the world in Portage, Michigan. This U.S. investment will strengthen Pfizer’s capability to produce and supply critical, life-saving injectable medicines for patients around
NEW YORK — Pfizer Inc. announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. These
NEW YORK — Pfizer Inc. has received approval from the Food and Drug Administration for IXIFI (infliximab-qbtx), a biosimilar of Remicade (infliximab) from Janssen Biotech Inc. Pfizer said the FDA cleared IXIFI, a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, for the treatment of patients with rheumatoid arthritis, Crohn’s disease, pediatric Crohn’s disease, ulcerative
NEW YORK — The first generic versions of Viagra, Pfizer Inc.’s blockbuster drug for erectile dysfunction, were launched this week in the United States by Teva Pharmaceutical Industries Ltd. and Greenstone LLC. Israel-based Teva said it’s offering sildenafil citrate tablets in dosages of 25 mg, 50 mg and 100 mg. Greenstone, a Peapack, N.J.-based Pfizer subsidiary,
NEW YORK — In a fine-tuning of its executive leadership, Pfizer Inc. has named Albert Bourla as chief operating officer, a newly created position. Pfizer said Bourla, 56, currently group president of the Pfizer Innovative Health business unit, is slated to start in the COO role on Jan. 1. With the move, chairman and chief
